UBS Maintains Buy on AdaptHealth, Lowers Price Target to $10
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $10.
Read original at benzingaStocks · News reference
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday
Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 21, 2026, 3:14 PM
- Checked
- Jul 21, 2026, 3:14 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
RBC Capital Maintains Outperform on AdaptHealth, Lowers Price Target to $8
RBC Capital analyst Ben Hendrix maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and lowers the price target from $15 to $8.
Read original at benzingaTruist Securities Maintains Buy on AdaptHealth, Lowers Price Target to $9
Truist Securities analyst David Macdonald maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $9.
Read original at benzingaCrude Oil Down Over 5%; McDonald's Earnings Top Views
U.S. stocks gain with Nasdaq up more than 2% on Tuesday. Dow up 1.79% to 54,129.35, Nasdaq up 2.22% to 26,490.24, S&P 500 up 1.64% to 7,725.48. Tech shares jump 3.8%, utilities down 0.5%. McDonald's beats earnings estimates. Ibotta, Backblaze, Corvex up, Adapthealth, Better Home & Finance, Clearpoint Neuro down.
Read original at benzinga8-K filing — American Healthcare REIT, Inc. (AHR)
Filed: 2026-08-24 AccNo: 0001193125-26-363616 Size: 1 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarKeybanc Maintains Overweight on American Healthcare REIT, Raises Price Target to $68
Keybanc analyst Austin Wurschmidt maintains American Healthcare REIT (NYSE:AHR) with a Overweight and raises the price target from $58 to $68.
Read original at benzinga